Clinical Trials Logo

Hepatic Steatosis clinical trials

View clinical trials related to Hepatic Steatosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05882214 Active, not recruiting - Hepatic Steatosis Clinical Trials

Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink

NMN-MeABD
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are: 1. if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom; 2. if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis.

NCT ID: NCT05654051 Active, not recruiting - Insulin Resistance Clinical Trials

The SLIM LIVER Study

SLIM LIVER
Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of a drug called semaglutide and to see whether it can reduce IHTG. IHTG will be measured by magnetic resonance imaging (MRI; an MRI machine contains a powerful magnet that uses simple radio waves to take pictures of organs). Semaglutide (brand name Ozempic®) is a drug that is used to treat people who have diabetes; it also causes weight loss and may provide some protection against cardiovascular disease and diabetes. In PLWH, the use of semaglutide to reduce weight and the level of IHTG are experimental.

NCT ID: NCT04704063 Active, not recruiting - NAFLD Clinical Trials

Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)

T3-NAFL
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Palm-derived tocotrienols have shown hepatoprotective effects in both animal and human studies. This study aims to investigate the effects of tocotrienols in hepatocellular lipid content using MRI. Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from simple fatty liver (steatosis, NAFL) to non-alcoholic steatohepatitis (NASH) to cirrhosis. NASH is the accumulation of fat in liver cells accompanied with inflammation that can lead to the scarring of the liver. Prevention of liver fibrosis by early introduction of low risk interventions such as lifestyle modification, diet control and nutraceuticals may help circumvent long-term healthcare costs associated with management of chronic NASH.

NCT ID: NCT03587727 Active, not recruiting - Obesity Clinical Trials

Hepatic Mitochondrial Function in Youth

MANGO
Start date: November 20, 2018
Phase:
Study type: Observational

Assess the impact of bariatric surgery on hepatic energy metabolism and glucose and insulin dynamics in obese youth

NCT ID: NCT02493153 Active, not recruiting - Hepatic Steatosis Clinical Trials

Hepatic Steatosis After Cholecystectomy

HSAC
Start date: October 2013
Phase: N/A
Study type: Observational

The investigators are very pleased to register the study entitled "A prospective study for the effect of cholecystectomy to the liver in consideration of hepatic steatosis 3months after cholecystectomy with Ultrasound". This study deals with prospective ultrasound study about hepatic steatosis development 3 months after cholecystectomy. This study was approved by the Institutional Review Board of the local institute. From Oct, 2013 to Jul, 2014, assessment of liver changes after cholecystectomy was carried out in 82 patients with gallbladder disease. In conclusion, the investigators thought that cholecystectomy might be considered as a risk factor for hepatic steatosis.